Dr. Diana Tichy

Dr. Diana Tichy

Dr. Diana Tichy

Position:

Scientist

Phone:

+49 6221 42 2261

Fax:

+49 6221 42 2397

Building:

TP 4

Room:

S4.223

Area of Work  

  • Design and analysis of clinical studies (phase I to IV) 
  • Accompying research of clinical studies, analysis of retrospective studies
  • Analysis of microarray data obtained from any experimental setting 
  • Research on simulation of high-dimensional data using plasmode data sets
  • My further research interest focuses on the application of Extreme Value Statistics in the framework of microarray data aiming in the estimation of tail distributions

 
Education and Background

  • Division of Biostatistics at the DKFZ since February 2013
  • Dr. rer. nat., Faculty of Mathematics and Informatics, University of Würzburg, 2012
  • 2007-2012, Research Assistant, Institut of Mathematics / University Hospital, University of Würzburg 
  • Diploma in Mathematics, University of Würzburg, 2007

 
Selected Publications  

  • Bonsack M, Hoppe S, Winter J, Tichy D, Zeller C, Küpper MD, Schitter E, Blatnik R, Riemer A: Performance evaluation of MHC class-I binding prediction tools based on an experimentally validated MHC-peptide binding dataset. Cancer Immunology Research (in review) 2018.
  • Groß J, Nattenmüller J, Hemmer S, Tichy D, Goldschmidt H, Bertsch U, Delorme S, Kauczor HU, Hillengass J, Merz M: Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma. Subgroup analysis of the prospective GMMG MM5 trial. Oncotarget 2017, 8(40):68460-68471.
  • Tichy D, Pickl J, Benner A, Sueltmann H: Experimental design and data analysis of Ago-RIP-Seq experiments for the identification of microRNA targets. Briefings in Bioinformatics 2017, 19(5):918-929.
  • Bickelhaupt S, Paech D, Kickingereder P, Steudle F, Lederer W, Daniel H, Götz M, Gählert N, Tichy D, Wiesenfarth M, Laun FB, Maier-Hein K, Schlemmer HP, Bonekamp D: Malignant suspicious breast lesions predicted by a radiomic signature from contrast agent-free diffusion MRI. Journal of Magnetic Resonance Imaging 2017, 46(2):604-616.
  • Wolf MB, Edler C, Tichy D, Röthke MC, Schlemmer HP, Herfarth K, Bonekamp D: Di_usion-weighted MRI treatment monitoring of primary hypofractionated proton and carbon ion prostate cancer irradiation using raster scan technique. Journal of Magnetic
    Resonance Imaging 2017, 46(3):850-860.
  • Pickl JM, Tichy D, Kuryshev V, Tolstov Y, Falkenstein M, Schüler J, Reidenbach D, Hotz-Wagenblatt A, Kristiansen G, Roth W, et al: Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. Oncotarget 2016, 7(37): 59589-59603.
  • Phillips E, Lang V, Bohlen J, Bethke F, Puccio L, Tichy D, Herold-Mende C, Hielscher T, Lichter P, Goidts V: Targeting atypical protein kinase C iota reduces viability in glioblastoma Stem-like cells via a notch signaling mechanism. International Journal
    of Cancer 2016, 139(8):1776-1787.
  • Burth S, Kickingereder P, Eidel P, Tichy D, Bonekamp D, Weberling L, Wick A, Löw S, Hertenstein A, Nowosielski M, Schlemmer HP, Wick W, Bendszus M, Radbruch A: Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. Neuro Oncology 2016, 18(12):1673-1679.

 

 

to top
powered by webEdition CMS